Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage ...

Nanoparticle-Mediated Photodynamic Therapy Takes on Triple-negative Breast Cancer

GA, UNITED STATES, February 4, 2026 / EINPresswire.com / — Researchers have developed a new biomimetic nanocomposite ...
GEN

CRISPR-Cas9 Targets Lung Cancer Using Cryo-Shocked Tumor Cells

Scientists from Zhejiang University have developed a novel delivery vehicle for CRISPR-Cas9 that is more effective than lipid nanoparticles (LNPs) in treating lung cancer. Rapid liquid nitrogen ...

Crispr Therapeutics: Very High Risk But Even Higher Potential Reward

CRISPR Therapeutics is rated 'Buy' for its blockbuster CASGEVY launch, robust cash position, and high upside despite significant risks. CASGEVY's gene-editing therapy targets severe SCD and TDT, with ...
Science Daily

CRISPR/Cas9 modifies euglena to create potential biofuel source

Through genome editing using CRISPR/Cas9, researchers stably create euglena mutants that can produce wax esters with improved cold flow, making the esters suitable as feedstock for biofuels. News ...
Seeking Alpha

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...
MedPage Today

Novel CRISPR-Cas9-Based Promising in ATTR Cardiomyopathy

CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to ...